The French Competition Authority fines a pharmaceutical company €15.3 M for preventing market entry of a generic (Arrow / Schering-Plough)

Introduction On 18th December 2013, the French Competition Authority handed down a significant decision in the pharmaceutical sector. The Competition Authority considered that Schering-Plough had abused its dominant position by impeding the entry of the generic product onto the market. In particular, Schering-Plough disparaged Arrow’s generic product, long before its launch on the market. Background Schering-Plough has been selling Subutex (which contains the buprenorphine molecule) since 1996, an opiate used to wean people off their addiction to drugs such as morphine, heroin and methadone. In 2006, after the Subutex patent expired, Arrow attempted to launch a generic version of Subutex. However, Arrow was astonished to note a real difficulty in selling its generic product. In

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

  • Fidal (Lyon)

Quotation

Karen Luzi, The French Competition Authority fines a pharmaceutical company €15.3 M for preventing market entry of a generic (Arrow / Schering-Plough), 18 December 2013, e-Competitions Bulletin Competition in the Pharmaceutical sector, Art. N° 63583

Visites 190

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues